ANNOUNCEMENT 30 Dec 2015In December 2015, the government of the Russian Federation announced a change in private-sector financial support.
NUMBER OF INTERVENTIONS
? ? 2013-2020
30 2015 1518
Russian Pharmaceutical Market (Current Review And Future Outlook Until 2020).
Opportunities For Swiss Companies
Regulations discourage foreign pharma in Russia
State programme "Development of the pharmaceutical and medical industries" for the period 2013--2020
On 30 December 2015 the Government of the Russian Federation approved Decree No. 1518. It contains a GTA-relevant state support addendum to the the state programme "Development of the pharmaceutical and medical industries" for the period 2013--2020 ("the programme").
Concretely, it adds the possibility for allocation of new subsidies from the federal budget. Their purpose is to partially compensate Russian organisations for the incurred costs for the implementation of projects for production of medicines and (or) production of pharmaceutical substances, for clinical trials, for other pharma-therapeutic medical goods, and for improvement of medical analogues by means of innovative drugs. Decree No. 1518 does not specify concrete denominations of medical goods and services.
From the 2016 federal budget are to be allocated 6.950 billion RUB (95.848 million USD as per the official RUB/USD exchange rate for 30 December 2015). The potentially affected foreign jurisdictions are identified on the basis of the 3rd and 4th provided sources.
The GTA includes state guarantees and other financial incentives that are likely to affect the restructuring and performance of firms facing international competition, whether from imports, in export markets, and from foreign subsidiaries.